Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376300 | 0.80 | ABL1 (0.43) | ABL1SCN5A | |
| SCHEMBL8103834 | 0.79 | NPY5R (0.65) | ABL1CHRM5SCN5ANPY5RKIF11 | |
| SCHEMBL8111753 | 0.79 | KIF11 (0.56) | ABL1CHRM5SCN5ANPY5RKIF11 | |
| SCHEMBL23302186 | 0.78 | ABL1 (0.40) | ABL1CHRM5SCN5A | |
| SCHEMBL10059520 | 0.78 | CHRM5 (0.44) | ABL1CHRM5SCN5A | |
| SCHEMBL1333400 | 0.77 | ABL1 (0.53) | ABL1SCN5AKIF11 | |
| SCHEMBL1230049 | 0.77 | SCN5A (0.48) | SCN5ANPY5RKIF11 | |
| SCHEMBL16215338 | 0.77 | GABBR2 (0.49) | SCN5AKIF11 | |
| SCHEMBL1230338 | 0.77 | CYP11B1 (0.53) | ABL1SCN5APRMT6NPY5R | |
| SCHEMBL1202876 | 0.77 | PRMT6 (0.42) | SCN5APRMT6NPY5RKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105524058-B | Pyrazolo [1,5 a] pyridine compounds and their and its application | 广州艾格生物科技有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-9169216-B2 | Method for preparation of 5-substituted pyrimidines | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140121375-A1 | METHOD FOR PREPARATION OF 5-SUBSTITUTED PYRIMIDINES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-01 | — | — | US | disclosed |
| EP-1019410-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2000-07-19 | — | — | EP | disclosed |
| US-6060469-A | Spiro-piperidine derivatives and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-05-09 | — | — | US | disclosed |
| WO-1997019084-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121375-A1 | METHOD FOR PREPARATION OF 5-SUBSTITUTED PYRIMIDINES | DPYD, TYMP, DUT | ABL1 748/4885CHRM5 316/4885SCN5A 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.